Back to top
more

Merus (MRUS)

(Real Time Quote from BATS)

$39.83 USD

39.83
531,950

-0.64 (-1.58%)

Updated Apr 19, 2024 03:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MRUS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Merus N.V. [MRUS]

Reports for Purchase

Showing records 1 - 20 ( 173 total )

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 1

02/29/2024

Company Report

Pages: 7

Bullish Ahead of Petosemtamab’s Interim Data in 1L HNSCC in 2Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 2

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 3

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 4

11/28/2023

Daily Note

Pages: 4

MCLA-129’s Update During ESMO Asia Helps Define Pathway Forward; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 5

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for MRUS 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 6

11/03/2023

Company Report

Pages: 7

Petosemtamab Takes Center Stage in 2024; Reit. Buy and $48 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 7

10/16/2023

Daily Note

Pages: 4

ESMO’23 Update Reinforces Positive INTERLINK-1 Read- Through, Coupled with Zeno Progress on All Fronts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 8

08/08/2023

Company Report

Pages: 7

Petosemtamab Pivotal HNSCC Pathway Takes Shape, with Peto + Pembro Data in 1H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 9

05/05/2023

Company Report

Pages: 7

Peto’s The Way To Go For HNSCC; Reit. Buy and Raising Our PT to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 10

04/18/2023

Daily Note

Pages: 4

Petosemtamab Development Path Becomes Clear with Impactful Update in HNSCC During AACR ’23

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 11

03/01/2023

Company Report

Pages: 7

Multiple Clinical Updates in ''23 Drives A Standout BsAb Platform; Reit. Buy and Modulating PT to $40

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 12

11/09/2022

Daily Note

Pages: 13

SITC Abstracts Part II

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 13

11/04/2022

Company Report

Pages: 7

The Argument of Tumor Agnostic or Tissue Specific Label for Zeno Back on the Table; Reit. Buy and Lowering Our PT to $39

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 14

11/03/2022

Company Report

Pages: 6

3Q22: Feedback From the FDA on the Lead Asset. PT Reduced to $39

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 15

11/03/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 16

10/27/2022

Daily Note

Pages: 4

Initial MCLA-129 Data Reports Encouraging Profile Which Should Not be Overinterpreted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 17

10/26/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 18

10/26/2022

Company Report

Pages: 11

Early Results of Bispecific AB Promising

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 19

10/11/2022

Industry Report

Pages: 9

Treatment Paradigm Pulse-A Prospective Look at EGFR Inhibitors in NSCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 20

08/09/2022

Company Report

Pages: 7

Zenocutuzumab Set to Explore Combinations and Cancers Outside NRG1+; Reit. Buy and $45 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party